The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.

Published

Journal Article

BACKGROUND: Vascular risk factors (VRF) may influence response to rivastigmine in Alzheimer's disease (AD). METHODS: AD patients who participated in a randomized, double-blind, placebo-controlled trial of rivastigmine patch and capsule treatment were stratified by baseline VRF status. Treatment response was evaluated using the AD Assessment Scale-cognitive subscale (ADAS-cog), AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale. RESULTS: ADAS-cog scores significantly improved in all rivastigmine-treated patients (p < 0.05 vs. placebo), except 9.5 mg/24 h patch-treated patients with VRF, and were significantly affected by VRF status in the study population as a whole. Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF. The ADCS-CGIC significantly improved in capsule-treated patients with, and patch-treated patients without VRF. Although non-significant, patients without VRF showed an apparent faster rate of placebo decline. CONCLUSION: VRF may influence AD progression and response to rivastigmine.

Full Text

Duke Authors

Cited Authors

  • Farlow, MR; Doraiswamy, PM; Meng, X; Cooke, K; Somogyi, M

Published Date

  • January 2011

Published In

Volume / Issue

  • 1 / 1

Start / End Page

  • 150 - 162

PubMed ID

  • 22163241

Pubmed Central ID

  • 22163241

Electronic International Standard Serial Number (EISSN)

  • 1664-5464

Digital Object Identifier (DOI)

  • 10.1159/000328745

Language

  • eng

Conference Location

  • Switzerland